Ledger. Australian venture funding, tracked

Professor, The University of Texas at Austin

Jennifer Maynard

Coverage

Stories naming Jennifer Maynard. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Funding announcement

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch, built on a University of Texas at Austin candidate; the article also recalls the company's early financings led by OneVentures.

Brandon BioCatalyst portfolio 9 Nov 2022 Biomedical Advanced Research and Development AuthorityBrandon CapitalHealthcare VenturesNIHOneVenturesOneVentures Innovation Fund IThe University of QueenslandThe University of Texas at AustinUniQuestUniversity of the Sunshine CoastVaxxasWE CommunicationAustralian GovernmentAmy MillerDr David L HoeyDr David MullerIlya FinkelsteinJason McLellanJennifer Maynard
Funding announcement

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas has begun an Australian Phase I trial of its needle-free COVID-19 vaccine patch; the article also recalls the company's founding financing led by OneVentures with Brandon Capital and other co-investors.

Brandon Capital portfolio 9 Nov 2022 Biomedical Advanced Research and Development AuthorityBrandon BioCatalystBrandon CapitalHealthcare VenturesNIHOneVenturesThe University of QueenslandThe University of Texas at AustinUniQuestUniversity of the Sunshine CoastVaxxasWE CommunicationAustralian GovernmentAmy MillerDr David L HoeyDr David MullerIlya FinkelsteinJason McLellanJennifer MaynardUniQuest

Something wrong? Tell us